Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, ...

Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy ...

[3] Asymptomatic relatives may have undiagnosed DCM, and relatives reported to have DCM may actually have other forms of cardiomyopathy such as ischemic cardiomyopathy. Classification into ...

Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing ...

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from ...

NYHA class III/IV Dilated (ischemic or idiopathic) cardiomyopathy Sinus rhythm >/= 55 bpm QRS >/= 120 ms PR interval >/= 150 ms ...

glasgow.ac.uk Objective The recent Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure ... do not reduce overall mortality in patients with non-ischaemic ...

Genome-wide association and multitrait analyses for dilated cardiomyopathy (DCM) using 9,365 cases and 946,368 controls provide insights into the mechanisms underlying DCM and myocardial ...